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Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease leading to inﬂammatory tissue damage in multiple
organs. The crude polysaccharides (BPs) isolated from the roots of Bupleurum smithii var. parvifolium have anticomplementary
activity and immunomodulatory functions on macrophages. To study its potential beneﬁt on SLE, we examined eﬀects of BPs on
MRL-lpr mice, which have similar disease features to human SLE. MRL-lpr mice were treated orally with BPs 15, 30, or 60mg
kg−1 day−1 for 12 weeks and their SLE characteristics were evaluated. The results revealed that BPs elongated life span, improved
kidney function, delayed lymphadenopathy, and reduced autoantibodies. It seemed to be mediated by inhibition of complement
andmacrophagesactivationandsuppressionofinterferon-γ (IFN-γ)andinterleukin-6(IL-6)geneexpressioninthekidney.These
results implicate that BPs may be an immunomodulator for the treatment of autoimmune diseases like SLE.
1.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease involving inappropriate inﬂammatory responses,
resulting in multiorgans dysfunctions like lymphadenopathy
and glomerulonephritis. It is characterized by a polyclonal
expansion of autoreactive lymphocytes and production of
multiple autoantibodies, mostly in young females [1]. The
main eﬀectors of disease pathology are the diverse autoan-
tibodies, immune complexes, complement activation, and
autoreactive cells [2].
As an important link between the innate and adaptive
immune system, monocytes/macrophages have been found
to play an essential role in the pathogenesis of SLE [3].
Altered functions of these cells may play a dynamic role not
only in the initiation of autoimmunity through abnormali-
tiesinphagocytosisbutalsointheperpetuationofthedisease
through abnormal signals such as increased costimulation of
autoreactive T and B cells and in tissue damage [4].
MRL-Faslpr/lpr (MRL-lpr) mice with Fas mutation spon-
taneously develop an autoimmune disease similar to human
SLE. Deposition of immune complex in the kidney triggers
the production of proinﬂammatory mediators, resulting in
macrophage and lymphocyte inﬁltration, and ultimately
to glomerulosclerosis with renal failure in these mice [5].
Aberrant macrophage activities have been shown in numer-
ous studies in MRL-lpr mice [6–8]. Indeed, MRL-lpr mice
provide a more attractive model because their syndrome is
rapid, spontaneous, and predictable.Becauseof this, weused
MRL-lpr mice to attempt to evaluate therapies.
Radix Bupleuri (dried roots of Bupleurum chinense or
Bupleurum scorzonerifolium), known as Chai-Hu, is one of
the most frequently prescribed crude herbs in the prescrip-
tions of traditional Chinese medicine for the treatment of
inﬂammatory diseases [9] and autoimmune diseases [10].
Our previous experiments conﬁrmed that crude polysac-
charide isolated from Bupleurum smithii var. parvifolium
(BPs) showed inhibitory properties toward complement
activation [11] and had potent immunomodulatory activity
on macrophages [12]. It had also been proved that BPs
have beneﬁcial eﬀect on autoimmune disease induced by
Campylobacter jejuni in BALB/c mice via inhibiting humoral2 Clinical and Developmental Immunology
immune hyperfunction and alleviating the activation of
complement [11]. The present work is to study the eﬀect of
BPs on MRL-lpr mice and to learn its possible mechanism.
2.MaterialsandMethods
2.1. Isolation and Characterization of Bupleurum Polysaccha-
rides (BPs). The roots of Bupleurum smithii var. parvifolium
were purchased from Shanghai Hua-Yu Chinese Materia
Medica Co. Ltd and its identity was veriﬁed by Profes-
sor Shenli Pan at Fudan University. A voucher specimen
(DFC-CH-H2003121602) of the plant material has been
deposited in the Herbarium of Materia Medica, Department
of Pharmacognosy, School of Pharmacy, Fudan University,
Shanghai, China. The isolation and chromatographic studies
of the crude polysaccharides from Bupleurum smithii var.
parvifolium were completed as previously described [11].
2.2. Mice and Experimental Protocol. Eight-week-old female
MRL-lpr and BALB/c mice were obtained from Slaccas-
Shanghai Lab Animal Ltd. (SPF II Certiﬁcate; number
SCXK2007–2005) and kept under speciﬁc pathogen free and
normal housing conditions in a 12-hour light and dark
cycle. All experimental protocols described in this study were
approved by the Animal Ethical Committee of School of
Pharmacy, Fudan University.
BPs and prednisone were ground and suspended in
normal saline for administration, respectively. In the lon-
gitudinal study, twelve-week-old BALB/c mice were orally
received normal saline as the control, and twelve-week-old
MRL-lpr mice were orally received normal saline, BPs 60, 30,
and 15mg·kg−1·day−1, or prednisone 5mg·kg−1·day−1 for
12 weeks.
During the physical exam, each mouse was palpated to
determine the extent of lymph node enlargement that was
present. Lymph node enlargement was scored as follows: 0,
none; 1, mild enlargement (palpable, but not easily visible);
2, moderate enlargement (easily visible, but not interfering
with mobility); and 3, severe enlargement (easily visible and
interfering with mobility regardless of extent of interference)
[13].
Urine was collected over 24h in metabolic cages and
stored at −80◦C at week 24. Mice were sacriﬁced at the
e n do fw e e k2 4o fa g ea n ds e r u mw a ss t o r e d−80◦C until
measurementofantinuclearantibodies.Lymphnode,spleen,
thymus,andkidneyswereremovedpromptlyandonekidney
from each mouse was stored into 10% formaldehyde before
further analysis. Remaining kidneys were snap frozen in
liquid nitrogen prior to storage at −80◦C. The index of
lymph node, spleen, or thymus was expressed as the ratio of
lymph node, spleen, and thymus wet weight (g) versus body
weight (g) (100×).
2.3. Immunoassay of Antibodies. Enzyme-linked immunos-
orbent assay (ELISA) was carried out for the detection of
speciﬁc antibodies in sera of MRL-lpr and BALB/c mice
(control group). For the detection of anti-dsDNA antibodies
and anti-ssDNA antibodies, 96-well plates (Costar, Corning,
N Y )w e r ec o a t e dw i t hc a l ft h y m u sD N A( S i g m a )o rd e n a -
tured calf thymus at 50μg/mL. 10μg/mL histone from calf
thymus (Sigma) was used for detection of antihistone anti-
bodies. Murine serum was diluted at 1:200 in phosphate-
buﬀered saline and horseradish-peroxide (HRP-) conjugated
goat anti-mouse IgG antibodies were diluted at 1:1000
(Sino-AmericanBiotechnologyCompany,Shanghai,China).
Optical density (OD) was monitored at 492nm using a well
scanner ELISA reader (Multiskan FC, Thermo scientiﬁc).
Results were indicated in Enzyme Index (EI). EI = 100 ×
ODtested /(MeanODcontrol group +3 SD)[14].
For the detection of total IgG, 96-well plates were
coated with goat anti-mouse IgG (Wuhan Boster Biological
Technology, Ltd.) 10 μg/mL, 100μL/well. Sera were diluted
at 1:10,000, 100μL/well. HRP-conjugated goat anti-mouse
IgG antibodies were added at a 1:5,000 dilutions. The
miceIgGstandard(Sino-AmericanBiotechnologyCompany,
Shanghai, China) was used for standard curve ﬁtting and
immunoglobulin concentration calculating.
2.4. Assessment of Creatinine and Urinary Protein. Mouse
creatininewasestimatedinserumsamplesusingaCreatinine
Jaﬀe method kit (FengHui Medical Technology Company,
Shanghai, China). Proteinuria was measured by Coomassie
b r i l l i a n tb l u et e s t[ 11]. Albumin (bovine serum) was used
to make standard curves. Murine urine was centrifuged at
1000×g for 10min. The supernatant was diluted at 1:3 in
normal saline. The optical density was measured at 540nm
after addition of Coomassie brilliant blue solution.
2.5. Hematoxylin and Eosin (H and E) Staining and Immuno-
histochemistry. The kidney was ﬁxed with 10% formalde-
hyde and embedded in paraﬃn. Sections of 5μm thick were
cut and stained with hematoxylin and eosin (H and E).
Glomerular injury was blindly semiquantiﬁed by a renal
pathologist. Sections were graded as follows: 0, normal; 1,
a small increase of cells in the glomerular mesangium; 2,
a larger number of cells in the mesangium; 3, complex
endocapillary hypercellularity sometimes with mild sclerosis
or necrosis; and 4, glomerular crescent formation, sclerosis,
tubular atrophy and casts [15]. Usually, there were diﬀerent
grade lesions observed in a kidney; the most severe alteration
was referred to as the grade of each mouse kidney and was
taken into analysis.
For the detection of IgG deposits, the 5μms e c t i o n sw e r e
deparaﬃnized, rehydrated, and incubated with peroxidase-
conjugated goat anti-mouse IgG (Sino-American Biotech-
nology Company, Shanghai, China). Staining was visualized
using chromogenic substrate solution 3-3  diaminobenzi-
dine (DAB).
2.6. Real-Time PCR. Total RNA was extracted from snap-
frozen kidneys using Trizol reagent (Invitrogen, USA), and
cDNA was synthesized from 2ug total RNA by using
random hexamers and SuperScript II Reverse Transcriptase
(Invitrogen). SYBR Green I Dye detection system was used
for quantitative PCR (qPCR) on Step One Plus Real-Time
PCR System (Applied Biosystems, USA). 2uL cDNA wasClinical and Developmental Immunology 3
ampliﬁed in a 20uL PCR reaction system using recombinant
Taq DNA polymerase (TAKARA, Japan). All reactions were
performed in triplicate, and negative controls contained no
template DNA. We used GAPDH RNA as an endogenous
control for normalization. cDNA was subjected to 2-step
PCR method: 95◦Cf o r2m i n ;4 0P C Rc y c l e s( 9 4 ◦Cf o r1 0s ,
59◦Cf o r1 0s ,a n d7 2 ◦C for 40s) to detect MCP-1, IFN-γ,
and IL-6 or subjected to 40 PCR cycles (94◦C for 10s, 57◦C
for 10s, and 72◦C for 40s) to detect MHC-II, and subjected
to 40 PCR cycles (94◦C for 10s, 57◦Cf o r1 0 s ,a n d7 2 ◦C
for 40s) to detect GAPDH. To verify that the primer pair
produced only a single product, a dissociation protocol was
added after thermocycling, determining dissociation of the
PCR products from 60 to 95◦C. Data were analyzed using the
comparative threshold cycle (ΔΔCt) method.
2.7. Western Blotting. Kidney tissues of mice (100mg) were
separated by 12% SDS-PAGE under reducing conditions
and transferred to PVDF membranes (Milipoler). Mem-
branes were blocked with Superblock overnight at room
temperature. Blots were probed with 1:200 dilution of
primary antibody for C3, F4/80, IFN-γ, IL-6, MCP-1, MHC-
II, and GAPDH (Santa Cruz, USA) for 2 hours in 5%
milk/TBST. Membranes were next incubated with 1:2,000
dilution peroxidase-labeled second antibody (Santa Cruz,
USA) for 2 hours. All membranes were visualized using DAB
buﬀer. Densitometric analysis of the ﬁlm was performed
usingaModelGS-2008imagingdensitometer(TANON)and
analyzed using TANON analysis software.
2.8. Statistical Analysis. Quantitative variables were ex-
pressed as means ± SD. One-way analysis of variance
(ANOVA) was used. If any signiﬁcant change was found,
post hoc comparisons were performed using Fisher’s PLSD.
NonparametricdatawereanalyzedbytheMann-WhitneyU-
test. P value < 0.05 was considered signiﬁcant.
3. Results
3.1. BPs Decreased Mortality Percentage and Lymphadenopa-
thy of MRL-lpr Mice. The eﬀect of BPs on survival was
estimated by comparing the BP-treated group with vehicle-
treated model group. After treatment for 12 weeks, the sur-
vival percentage of MRL-lpr mice (24-week-old) increased
in BP- 30mg·kg−1·day−1- (100%), BP- 60mg·kg−1·day−1-
(100%) and Prednisone- (100%) treated groups (Figure 1).
T h el y m p h a d e n o p a t h yo fM R L - l p rm i c ew a sg r a d e d
as lymph node enlargement. There was no signiﬁcant
diﬀerence in lymphadenopathy among ﬁve groups at 16
weeks of age. BPs 60mg·kg−1·day−1 signiﬁcantly delayed the
lymphadenopathy after 8 weeks of treatment and prednisone
after 9 weeks of treatment (P<0.05) (Table 1).
3.2. BPs Decreased Organ Index of MRL-lpr Mice. The index
of lymph node, thymus, and spleen increased signiﬁcantly
i nv e h i c l e - t r e a t e dm o d e lg r o u pw h e nc o m p a r e dw i t hc o n t r o l
group. BPs inhibited lymph node swelling (P<0.01),
administration of 30 and 60mg·kg−1·day−1 BPs inhibited
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Figure 1: Eﬀect of BPs on survival rate of MRL-lpr mice. MRL-
lpr mice were grouped randomly and treated with BPs 15, 30, and
60mg·kg−1·day−1, prednisone 5mg·kg−1·day−1,o rm o d e lf r o m
week 12 to week 24 (n = 8pergroup);weredataexpressedasmeans
± SD.
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Figure 2: Eﬀect of BPs on the index of lymph node, thymus, and
spleen in BALB/c and MRL-lpr mice. MRL-lpr mice were grouped
randomly and treated with BPs 15, 30, and 60mg·kg−1·day−1,
prednisone 5mg·kg−1·day−1, or model from week 12 to week 24;
data were expressed as means ± SD (n = 6–8); ∗P<0.05, ∗∗P<
0.01; ∗∗∗P<0.001 compared with vehicle treated-model group,
tested by ANOVA and Fisher’s PLSD.
thymus swelling (P<0.05), while prednisone treatment
signiﬁcantlydecreasedtheindexoflymphnode,thymus,and
spleen (P<0.05) (Figure 2).
3.3. BPs Reduced Autoantibody and Total IgG Levels in MRL-
lpr Mice. The sera were collected from MRL-lpr and BALB/c
mice to assay autoantibody concentration by ELISA. Anti-
dsDNA, anti-ssDNA, and anti-histone antibody levels were
signiﬁcantly elevated in the vehicle-treated MRL-lpr mice
(model group) compared with BALB/c mice (control group)
(P<0.001) (Figure 3) and were signiﬁcantly reduced4 Clinical and Developmental Immunology
Table 1: Eﬀect of BPs on lymphadenopathy of MRL-lpr mice.
Weeksof age
lymphadenopathy score
Model BPs Prednisone
15mg·kg−1 30mg·kg−1 60mg·kg−1 5mg·kg−1
16 0 (0∼1) 0.5 (0∼1) 1 (0∼1) 0 (0∼1) 0 (0∼0)
18 1 (0∼2) 1.5 (0∼2) 1 (0∼2) 0 (0∼2) 0 (0∼1)
20 2 (0∼3) 2 (0∼3) 1.5 (0∼3) 0 (0∼3)a 1( 0 ∼2)
21 2 (1∼3) 2 (0∼3) 2 (0∼3) 0 (0∼3)a 1( 0 ∼2)a
22 3 (2∼3) 2 (0∼3) 2 (0∼3) 0 (0∼3)b 1( 0 ∼2)b
23 3 (2∼3) 3 (0∼3) 2.5 (0∼3) 0 (0∼3)b 1( 0 ∼3)a
24 3 (2∼3) 3 (0∼3) 3 (0∼3) 0 (0∼3)b 1.5 (0∼3)a
note: Data were expressed as median (minimum∼maximum) (n = 6–8); aP<0.05, bP<0.01 compared with vehicle treated model group, tested by Mann-
Whitney U test.
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Figure 3: Eﬀect of BPs on antinuclear antibodies and total IgG production in BALB/c and MRL-lpr mice. MRL-lpr mice were grouped
randomly and treated with BPs 15, 30, and 60mg·kg−1·day−1, prednisone 5mg·kg−1·day−1, or model from week 12 to week 24; data were
expressed as means ± SD (n = 6–8); ∗∗∗P<0.001 compared with vehicle-treated model group, tested by ANOVA and Fisher’s PLSD.
Enzyme Index = 100 ×ODtested /(MeanODcontrol group +3SD).
by BPs 15, 30, 60, or prednisone 5mg·kg−1·day−1 (P<
0.001). It was indicated that BPs blocked the production of
autoantibodies in MRL-lpr mice, which are closely related to
SLE.
Furthermore, total IgG levels were assayed. Similarly,
total IgG levels were signiﬁcantly elevated in the vehicle
treated MRL-lpr mice compared with control group (P<
0.001) (Figure 3) and were reduced by BPs 15, 30, 60, or
prednisone 5mg·kg−1·day−1 signiﬁcantly (P<0.001).
3.4. BPs Impaired Proteinuria and Reduced Serum Creatinine
ofMRL-lprMice. ToevaluatewhetherBPshadeﬀectsonkid-
ney function, MRL-lprmice weretreated by BPsfor12 weeks
and urine samples were collected for protein determination.
In comparison with control group, model group exhibited
signiﬁcant increase in the level of urinary protein (P<
0.001), indicating a certain degree of kidney dysfunction.
However, BPs treatment resulted in a reduction in the levels
of urinary protein (Figure 4). BPs 60mg·kg−1·day−1 and
prednisone 5mg·kg−1·day−1 signiﬁcantly reduced urinary
protein level (P<0.01).
At 24 weeks of age, MRL-lpr mice showed increased
serum creatinine levels (P = 0.057), BPs treatment mildly
reduced serum creatinine levels, but only 30mg·kg−1·day−1
group showed signiﬁcance (Figure 4).
3.5. BPs Suppressed Lupus Nephritis and Reduced Renal IgG
Deposition in MRL-lpr Mice. We compared the extent of
nephritis between vehicle-treated and BPs-treated MRL-lpr
mice at 24 weeks. Vehicle-treated MRL-lpr mice developed
diﬀuse proliferative glomerulonephritis presented as diﬀuse
mesangial matrix expansion, profound mesangial cell pro-
liferation, and focal segmental glomerulosclerosis. Cellular
crescents and global glomerulosclerosis were often seen, and
the number of both resident cells and inﬁltrating leukocytes
was increased in glomeruli. Most animals revealed pro-
found tubulo interstitial inﬂammation as characterized by
periglomerular and diﬀuse interstitial leukocyte inﬁltrates,Clinical and Developmental Immunology 5
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Figure 4: Eﬀect of BPs on urinary protein and serum creatinine levels of MRL-lpr and BALB/c mice. MRL-lpr mice were grouped randomly
and treated with BPs 15, 30, and 60mg·kg−1·day−1, prednisone 5mg·kg−1·day−1, or model from week 12 to week 24; mice were sacriﬁced
and the supernatant of urine was diluted 1:3 in normal saline; the serum creatinine was measured with Jaﬀe method; data were expressed as
means ± S.D. (n = 6–8); ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 compared with vehicle-treated model group, tested by ANOVA and Fisher’s
PLSD.
Table 2: Eﬀect of BPs on glomerulonephritis scores of BALB/c and MRL-lpr mice.
Glomerulonephritis score
Control Model BPs Prednisone
15mg·kg−1 30mg·kg−1 60mg·kg−1 5mg·kg−1
0(0∼1)c 3.5(3∼4) 2(1∼3)c 2(1∼2)c 2(1∼2)c 1.5(1∼2)c
note: Data were expressed as median (minimum∼maximum) (n = 6–8); bP<0.001 compared with vehicle-treated model group, tested by Mann-Whitney U
test.
tubular atrophy, and intraluminal cast formation. Treatment
with BPs suppressed lupus nephritis as documented by
a signiﬁcant reduction of the glomerulonephritis scores
that encompasses glomerular cell proliferation, endocapil-
lary hypercellularity, crescent formation, sclerosis, tubular
atrophy and casts (Table 2, Figure 5).
To determine whether BPs might aﬀect renal disease by
reducing IgG deposition in the kidneys, tissue sections from
mice were stained for the presence of IgG. Vehicle-treated
MRL-lpr mice showed a patchy dense immunoperoxidase
indicativeofmesangialandtubulointerstitialIgGdeposition.
In contrast, BPs treatment signiﬁcantly decreased IgG depo-
sition (Figure 5).
3.6. BPs Suppressed Inﬂammatory Mediators and Markers
Expression in Kidney. Using RT-PCR and Western blotting,
weexaminedtheexpressionofIFN-γ,IL-6,MCP-1,MHC-II,
and F4/80 in the kidney of mice at 24 weeks. The expression
of IFN-γ, IL-6, MCP-1 mRNA, and protein was greatly
elevated in vehicle-treated MRL-lpr mice and was reduced
in varying degree from BP-treated mice compared with the
vehicle-treated mice. BPs treatment reduced the mRNA and
protein expression of the surface marker MHC-II and F4/80
(Figures 6 and 7).
C3 levels were also reduced in the kidney of BPs
treatment group, as was shown in Western blotting results
(Figure 7).
4. Discussion
Systemic lupus erythematosus is a chronic autoimmune
inﬂammatory disease that aﬀects various organs, including
skin, joint, kidney, and blood. Even without clear patho-
genesis mechanism, it has been suggested that the main
eﬀectors of disease pathology are the diverse autoantibodies,
immune complexes, complements, and autoreactive cells.
Altered biology of immune cells and possibly other cell types
invariably contributes to the progression of the diseases [2].
Macrophages have been considered to play important
roles in the pathogenesis of SLE in numerous studies [4].
Owing to the intrinsic defects of macrophages, SLE is one
of the widely acknowledged examples in which apoptotic6 Clinical and Developmental Immunology
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Figure 7:ProteinexpressionofIFN-γ,IL-6,MCP-1,MHC-II,F4/80,andC3inthekidneysofMRL/lprmice.(a)RenalexpressionsofIFN-γ,
IL-6, MCP-1, MHC-II, F4/80, and C3 were examined by Western blot analysis. The presented blot was a representative of those obtained
from three mices. GAPDH was used as loading control. (b) Results of quantitative analysis were expressed as means ± S.D. ratio of IFN-γ,
IL-6, MCP-1, MHC-II, F4/80, and C3 to GADPH (n = 3). ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 compared with vehicle-treated model group,
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cell clearance is disturbed in both mice and patient [3].
Recent studies also conﬁrmed that aberrant function of
lupus macrophages appeared to play a dynamic role in the
initiation and perpetuation of the systemic autoimmune
response and organ damage [4]. Moreover, aberrant mono-
cyte surface marker expression and numerous abnormalities
of the cytokine network have been described in patients
suﬀering from SLE [3].
Our laboratory has done a series of experiments con-
cerning the eﬀect of crude Bupleurum polysaccharide (BPs)
on the immune system. It was suggested that BPs have
potent immunomodulatory activity on macrophages ex vivo
by enhancing phagocytic activities and inhibiting LPS-
induced production of proinﬂammatory mediators [12]. It
had been demonstrated in our previous study that BPs were
a major component that contributed to the anticomplemen-
tary activity and had a beneﬁcial eﬀect on systemic lupus
erythematosus-like syndrome induced by CJ-S131 in BALB/c
mice [11]. BPs also inhibited LPS-induced phosphorylation
of NF-κB, TNF-α,I L - 1 β, IL-6, IL-12, and IFN-β production
in peritoneal macrophages (in press).
Here we ﬁnd that BPs treatment for 12 weeks has several
beneﬁcialeﬀectsonMRL-lprmiceincludingprotectionfrom
lethality, amelioration of glomerulonephritis, improvement
of kidney function, and prevention of lymphadenopathy
and thymus enlargement. The improved pathology was
associated with reduced production of autoantibodies and
inhibited expression of inﬂammatory cytokines and chemo-
tactic factors in the kidneys. We suggest that these beneﬁtial
eﬀects might be related to BPs anticomplement activity
and immunomodulatory functions on macrophages. Since
analyses on blood, urine, and kidney were performed at the
end of the treatment period and the sickest mice in model
group had died, the ﬁnal analyses are likely not an accurate
measure of the eﬀects of these agents. More experiments will
be needed and the analyses of desease progression should be
carried out in our further experiment.
In healthy individuals, the immune system defends the
body against microbes by distinguishing self from foreign
antigens. For reasons not completely understood, immune
tolerance against self-antigens fails in SLE and the immune
system actively responds to a wide array of autoantigens
[16]. Antinuclear antibodies such as anti-dsDNA antibodies
are unique to patient with SLE [17]. One of the most
important features of anti-dsDNA antibody is its association
withglomerulonephritis[18].Inthepresentstudy,theserum
from vehicle-treated MRL-lpr mice had higher levels of
total IgG, which may contain a large amount of antinuclear
antibodies (ANA) mainly. The kidney sections also had
higherIgGdepositionandexpressedhypercellularglomeruli.
High levels of protein in urine and creatine in sera also
indicated kidney dysfunction in MRL-lpr mice. According
to the previous results, it is indicated that the kidney
dysfunction in MRL-lpr mice might be related to their
aberrant immune responses. We demonstrated that BPs
decreased the total IgG, anti-dsDNA, anti-ssDNA, and anti-
histone antibodies, as well as renal IgG deposition, reduced
glomerular hypercellularity, and suppressed lupus nephritis
inMRL-lprmice.Therefore,itissuggestedthatBPsimproves
glomerulonephritis of MRL-lpr mice through modulation of
these pathological phenomena.
Lupus nephritis is triggered by glomerular immune com-
plex deposits that activate the components of the classical
complement pathway, which ﬁnally leads to the assembly
of membrane attack complex [19]. In the present study,
the favorable eﬀects of BPs treatment on markers of active
lupus nephritis were associated with a signiﬁcant reduction
of complement C3 in kidney, a marker of intraglomerular
complement activation. This was in line with our previous
ﬁndings that BPs had anticomplementary activity.
Leukocyte inﬁltration is a hallmark of severe lupus
nephritis, and macrophages play an important role in
ampliﬁcation of the inﬂammatory process in the kidney
[20].MHC-IIisanimportantmoleculeexpressedonantigen
presenting cells, such as macrophages, dendritic cells, and
B cells. Enhanced MHC class II antigen expression is a
common feature of autoimmunity and may play a key role
in the initiation and progression of lupus nephritis [21].
F4/80 is a cell surface glycoprotein predominantly expressed
on murine macrophages [22]. In this study, renal RT-PCR
and Western blotting revealed that MHC-II and F4/80 were
signiﬁcantlyupregulatedinthekidneyofMRL-lprmice.This
is likely the reﬂection of aberrant activation and increased
inﬁltration of macrophages in this model [4]. We found
that the expressions of MHC-II and F4/80 were signiﬁcantly
inhibited by BPs, which might reﬂect the immune inhibitory
eﬀe c to fB P so no v e r a c t i v a t e dm a c r o p h a g e s .
MCP-1 can induce transendothelial migration of mono-
cytes, and inﬁltration of monocytes/macrophages can in
turn facilitate tissue destruction [23]. MCP-1 deﬁcient MRL-
lpr mice were protected from progressive renal injury by
reduced leukocyte recruitment [24]. In this study, BPs
treatment resulted in a decrease in renal expression of MCP-
1, indicating that the eﬀect of BPs on kidney inﬂammation
might be mediated by reduced MCP-1 expression and
macrophage recruitment.
Inﬁltrating mononuclear cells are the major source of IL-
6 in diseased kidneys aﬀected by lupus nephritis [25], IL-6
can in return promote macrophage activation, it is elevated
in the serum and urine of some lupus patients, and murine
lupus models support a role for IL-6 in nephritis [26, 27].
In our previous study, we found that BPs decreased LPS-
induced excessive production of NO and proinﬂammatory
cytokines, including IL-1β,I L - 6 ,a n dT N F - α, but had mild
eﬀects on these cytokines when they were in physiologic
levels [12]. We found that the renal expression of IL-6 was
signiﬁcantly elevated in the kidney of MRL-lpr mice and was
inhibited by BPs treatment, indicating the suppression eﬀect
of BPs on macrophage secretions.
Tissue macrophages can be recruited and activated as
a consequence of the actions of a range of inﬂammatory
mediators such as cytokines. IFN-γ is increased in the serum
of some SLE patients and its level has been shown to
correlate with disease activity [28]. Furthermore, IFN-γ is a
potent cytokine in inducing MHC-II antigen expression in
inﬁltrating monocytes [29]. We found that the expression
of IFN-γ was signiﬁcantly elevated in the kidney of MRL-
lpr mice and was inhibited by BPs treatment, indicating that10 Clinical and Developmental Immunology
the anti-inﬂammatory eﬀects of BPs might also be asso-
ciated with decreased renal expression of proinﬂammatory
cytokines.
In addition to the local suppression of macrophages,
the therapeutic eﬀects of BPs might also be related to a
systemic blunting of autoimmunity, as reﬂected by decreased
serum levels of autoantibodies and renal immune complex
deposition.Sincemacrophage-derivedcytokinesarerequired
for the diﬀerentiation of B cells into antibody-secreting
plasma cells [30] and for the survival and proliferation of
B cells [31], one attractive hypothesis could be that the
inhibitory eﬀect of BPs on autoantibody production and
deposition might be mediated by macrophages. Another
plausible hypothesis could be that the eﬀect of BPs treatment
is due to less autoantibody deposition in the kidneys with
all the other eﬀects being secondary. Although our previous
work showed that BPs has an eﬀect on macrophages, and
in this study we found a decrease in surface markers and
cytokines associated with macrophages (either recruiting
them, activating them, orproduced by them),furtherstudies
are needed to identify whether macrophages are the direct
function target of BPs treatment.
In summary, this study demonstrated that BPs improves
lupus nephritis mainly by suppressing abnormal autoimmu-
nity of SLE. Our analysis proves the therapeutic eﬃcacy of
BPs in the treatment of SLE in MRL-lpr mice. Taken with the
current data, BPs could be a new agent for the treatment of
autoimmune disease.
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